Literature DB >> 31149288

PROGNOSTIC FACTORS IN PATIENTS WITH SURGICAL RESECTION OF PANCREATIC NEUROENDOCRINE TUMOURS.

S O Dima1,2, T Dumitrascu1, C Pechianu2,3, R T Grigorie1, V Brasoveanu1, A Sorop2, I Lupescu4, R Purnichescu-Purtan5, A Croitoru1,6, N Bacalbasa1,2, A Tanase6, D R Tomescu1, V Herlea3,6, I Popescu1,6.   

Abstract

CONTEXT: Pancreatic neuroendocrine tumours (PanNETs) are rare pancreatic neoplasms. PanNETs can be treated by multimodal approach including surgery, locoregional and systemic therapy.
OBJECTIVE: The aim of the present study is to evaluate predictive factors of overall survival in patients with PanNETs surgically treated at a single center. SUBJECTS AND METHODS: The study group consisted of 120 patients with PanNETs who had undergone surgery at the Center of Digestive Diseases and Liver Transplantation of Fundeni Clinical Institute, Bucharest, Romania. Surgical resection of the primary tumor was performed in 110 patients.
RESULTS: Tumor size > 2 cm (p=0.048) (90% CI) lymph node involvement (p=0.048), ENET grade (p<0.001), distant metastases (p<0.001), Ki 67 index (<2%, 2-5%, 5-10%, 10-20%, >20%) (p<0.001) were identified as significant prognostic factors for OS on univariate analysis. Using multivariate Cox proportional regression model we found that distant metastases and Ki 67 index were independent risk factors for the survival outcome.
CONCLUSIONS: Surgery with curative intent should be considered in all cases if clinically appropriate and technically feasible. High grade (Ki67 index ≥10%) tumours were associated with a 2- fold increase in risk of death as compared to those with a Ki67 <10%.

Entities:  

Keywords:  neuroendocrine; pancreatic; prognostic factors; surgery

Year:  2018        PMID: 31149288      PMCID: PMC6525773          DOI: 10.4183/aeb.2018.389

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  33 in total

Review 1.  Surgery for primary pancreatic neuroendocrine tumors.

Authors:  Jeffrey A Norton
Journal:  J Gastrointest Surg       Date:  2006-03       Impact factor: 3.452

2.  Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas.

Authors:  Quyen D Chu; Hank C Hill; Harold O Douglass; Deborah Driscoll; Judy L Smith; Hector R Nava; John F Gibbs
Journal:  Ann Surg Oncol       Date:  2002-11       Impact factor: 5.344

3.  Neuroendocrine tumours of the pancreas: predictors of survival after surgical treatment.

Authors:  N P Jarufe; C Coldham; T Orug; A D Mayer; D F Mirza; J A C Buckels; S R Bramhall
Journal:  Dig Surg       Date:  2005-07-20       Impact factor: 2.588

4.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

5.  Resection of pancreatic neuroendocrine tumors: results of 70 cases.

Authors:  Kevork K Kazanjian; Howard A Reber; Oscar J Hines
Journal:  Arch Surg       Date:  2006-08

6.  Differences in survival by histologic type of pancreatic cancer.

Authors:  Megan Dann Fesinmeyer; Melissa A Austin; Christopher I Li; Anneclaire J De Roos; Deborah J Bowen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-07       Impact factor: 4.254

Review 7.  Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors.

Authors:  Henning Dralle; Sabine L Krohn; Wolfram Karges; Bernhard O Boehm; Michael Brauckhoff; Oliver Gimm
Journal:  World J Surg       Date:  2004-11-11       Impact factor: 3.352

8.  Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors.

Authors:  Vikram Deshpande; Carlos Fernandez-del Castillo; Alona Muzikansky; Anita Deshpande; Lawrence Zukerberg; Andrew L Warshaw; Gregory Y Lauwers
Journal:  Am J Surg Pathol       Date:  2004-09       Impact factor: 6.394

9.  Incidence and management of malignant digestive endocrine tumours in a well defined French population.

Authors:  C Lepage; A M Bouvier; J M Phelip; C Hatem; C Vernet; J Faivre
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  5 in total

Review 1.  Debulking Surgery for Moderately Differentiated Neuroendocrine Gastric Carcinoma - A Case Report and Literature Review.

Authors:  Nicolae Bacalbasa; Iuliana Halmaciu; Ciprian Bolca; Adrian Neacsu; Dragos Cretoiu; Cristian Balalau; Camelia Diaconu; Laura Iliescu; Alexandru Filipescu; Cora Pop; Irina Balescu
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 2.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

3.  Pancreatoduodenectomy En Bloc With Vascular Resections in Borderline Resectable Pancreatic Cancer.

Authors:  Nicolae Bacalbasa; Adina Croitoru; Irina Balescu; Simona Dima; Vladislav Brasoveanu; Mihaela Vilcu; Iulian Brezean
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

4.  LARGE CELL METASTATIC PANCREATIC NEUROENDOCRINE CARCINOMA TREATED WITH SOMATOSTATIN ANALOGUES - CASE REPORT AND LITERATURE REVIEW.

Authors:  A Croitoru; I Dinu; V Herlea; G Becheanu; M Grasu; I Lupescu; S O Dima; F Buica; T Dumitrascu; C Lungulescu; V M Croitoru; A Tanase; S M Negru; I M Gramaticu
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Jul-Sep       Impact factor: 0.877

5.  A tool to predict survival in stage IV entero-pancreatic NEN.

Authors:  M Tarquini; M R Ambrosio; M Albertelli; P B de Souza; R Gafà; I Gagliardi; A Carnevale; P Franceschetti; M C Zatelli
Journal:  J Endocrinol Invest       Date:  2020-09-06       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.